<div id="readability-page-1"><p>The Manufacturers Life Insurance Company lessened its holdings in shares of  Novo Nordisk A/S (NYSE:NVO - Free Report) by 58.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,251 shares of the company's stock after selling 59,010 shares during the quarter. The Manufacturers Life Insurance Company's holdings in Novo Nordisk A/S were worth $3,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li></ul><p>A number of other hedge funds have also recently modified their holdings of the business. Diversified Trust Co increased its position in  Novo Nordisk A/S by 13.9% in the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company's stock worth $279,000 after buying an additional 395 shares in the last quarter.  First Hawaiian Bank grew its stake in shares of  Novo Nordisk A/S by 30.3% during the 4th quarter. First Hawaiian Bank now owns 22,259 shares of the company's stock valued at $1,915,000 after acquiring an additional 5,171 shares during the period.  ORG Partners LLC increased its holdings in  Novo Nordisk A/S by 181.7% in the 4th quarter. ORG Partners LLC now owns 1,003 shares of the company's stock worth $86,000 after acquiring an additional 647 shares in the last quarter.  Wealth Enhancement Advisory Services LLC raised its stake in  Novo Nordisk A/S by 0.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company's stock worth $24,988,000 after acquiring an additional 1,051 shares during the period.  Finally, A. D. Beadell Investment Counsel Inc. boosted its position in shares of  Novo Nordisk A/S by 41.1% in the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company's stock worth $1,119,000 after purchasing an additional 3,787 shares during the period. Institutional investors own  11.54% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several analysts have recently commented on the stock. Guggenheim downgraded shares of Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, April 17th. BMO Capital Markets  restated a &#34;market perform&#34; rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an &#34;underperform&#34; rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a &#34;strong-buy&#34; rating in a research note on Monday, April 28th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a &#34;sell&#34; rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned  a buy rating and two have issued  a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $135.00.</p><ul><li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li></ul><p><b>Get Our Latest Report on NVO</b></p><h2>Novo Nordisk A/S Trading Down 4.1 %</h2><p>NVO stock opened at $64.78 on Friday. The firm has a fifty day moving average price of $69.65 and a 200 day moving average price of $86.58. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a market cap of $290.72 billion, a PE ratio of 19.69, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. </p><ul><li>Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter, compared to analysts' expectations of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%.  Sell-side analysts anticipate that  Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year. </p><h2>Novo Nordisk A/S Profile</h2> (Free Report)<p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Investing in Travel Stocks Benefits</li><li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li><li>Consumer Discretionary Stocks Explained</li><li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li><li>10 Best Airline Stocks to Buy</li><li>Is Energy Transfer Undervalued or a Value Trap?</li></ul><p><strong>Want to see what other hedge funds are holding NVO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>The Manufacturers Life Insurance Company reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 58.3% in Q4, selling 59,010 shares and retaining 42,251 shares valued at $3.63 million. Other hedge funds also adjusted their positions, with varying increases and decreases in their stakes. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $135.00. Novo Nordisk's stock is currently trading at $64.78, down 4.1%.</p>

The Manufacturers Life Insurance Company Sells 59,010 Shares of Novo Nordisk A/S (NYSE:NVO)